Abstract
Pharmacophore models are widely used as efficient virtual screening (VS) filters for the target-directed enrichment of large compound libraries. However, the generation of pharmacophore models that have the power to discriminate between active and inactive molecules traditionally requires structural information about ligand-target complexes or at the very least knowledge of one active ligand. The fact that the discovery of the first known active ligand of a newly investigated target represents a major hurdle at the beginning of every drug discovery project underscores the need for methods that are able to derive high-quality pharmacophore models even without the prior knowledge of any active ligand structures. In this work, we introduce a novel workflow, called apo2ph4, that enables the rapid derivation of pharmacophore models solely from the three-dimensional structure of the target receptor. The utility of this workflow is demonstrated retrospectively for the generation of a pharmacophore model for the M2 muscarinic acetylcholine receptor. Furthermore, in order to show the general applicability of apo2ph4, the workflow was employed for all 15 targets of the recently published LIT-PCBA dataset. Pharmacophore-based VS runs using the apo2ph4-derived models achieved a significant enrichment of actives for 13 targets. In the last presented example, a pharmacophore model derived from the etomidate site of the α1β2γ2 GABAA receptor was used in VS campaigns. Subsequent in vitro testing of selected hits revealed that 19 out of 20 (95%) tested compounds were able to significantly enhance GABA currents, which impressively demonstrates the applicability of apo2ph4 for real-world drug design projects.
| Original language | English |
|---|---|
| Pages (from-to) | 101-110 |
| Number of pages | 10 |
| Journal | Journal of Chemical Information and Modeling |
| Volume | 63 |
| Issue number | 1 |
| DOIs | |
| Publication status | Published - 9 Jan 2023 |
Funding
The authors J.H., T.L., and T.S. gratefully acknowledge the financial support by the NeuroDeRisk project, which has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement no 821528. This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation program and EFPIA. The author A.G. has received funding from the Austrian Science Fund in the MolTag doctoral program FWF W1232. Open Access is funded by the Austrian Science Fund (FWF).
Austrian Fields of Science 2012
- 301207 Pharmaceutical chemistry